Cloud Banner

Medical Devices

Image

Global Laboratory-Developed Tests (LDTs) Market – Industry Trends and Forecast to 2030

  • Medical Devices
  • Published Report
  • Jul 2023
  • Global
  • 350 Pages
  • No of Tables: 1020
  • No of Figures: 80

Global Laboratory-Developed Tests (LDTs) Market, By Test Type (Clinical Chemistry and Immunology, Critical Care, Hematology, Molecular Diagnostics,  Microbiology, and Other Test), Product Type (Consumables, Analyzers and Instruments, and Accessories), Sample Type (Blood, Urine, Tissue, Cerebrospinal Fluid (CSF), and Others), Therapeutic Area (Infections, Genetic Disorders, Oncology/Cancer, Autoimmune Disease, Urology, Gynecology, and Others), Gender (Male, and Female), Age Group (Geriatrics, Adult, and Pediatric), End Users (Hospital-Based Labs, Stand-Alone Labs, Diagnostic Chains, Academic Institutes, Clinical Research Organizations, Specialty Diagnostic Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, Third Party Distributors, and Others)- Industry Trends and Forecast to 2030.

Laboratory-Developed Tests (LDTs) Market

Laboratory-Developed Tests (LDTs) Market Analysis and Insights

The increasing demand for personalized medicines and the rapidly growing pharmaceutical and medical industries is enhancing the demand for the market. The rising healthcare expenditure for better healthcare services is also attributed to market growth. The major market players are highly focused on product launches during the period. In addition, the government and regulatory bodies are supporting market players with product approval due to emergence. The market is growing in the forecast year due to the high demand for precision medicine and targeted therapy. However, stringent quality control and standardization for LDTs is expected to hamper the market growth.

Laboratory-Developed Tests (LDTs) MarketLaboratory-Developed Tests (LDTs) Market

Data Bridge Market Research analyzes that the global Laboratory-developed tests (LDTs) market is expected to grow at a CAGR of 10.7% during the forecast period of 2023 to 2030.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Year

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in Million, and Pricing in USD

Segments Covered

By Test Type (Clinical Chemistry and Immunology, Critical Care, Hematology, Molecular Diagnostics,  Microbiology, and Other Test), Product Type (Consumables, Analyzers and Instruments, and Accessories), Sample Type (Blood, Urine, Tissue, Cerebrospinal Fluid (CSF), and Others), Therapeutic Area (Infections, Genetic Disorders, Oncology/Cancer, Autoimmune Disease, Urology, Gynecology, and Others), Gender (Male, and Female), Age Group (Geriatrics, Adult, and Pediatric), End Users (Hospital-Based Labs, Stand-Alone Labs, Diagnostic Chains, Academic Institutes, Clinical Research Organizations, Specialty Diagnostic Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, Third Party Distributors, and Others)

Countries Covered

U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, and the Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and rest of Middle East and Africa

Market Players Covered

F. Hoffmann-La Roche Ltd, bioMérieux, Inc., Sysmex Corporation, Biomerica, Inc., and Bio-Rad Laboratories, Inc. , BD, Quest Diagnostics Incorporated, Hologic, Inc., Siemens Medical Solutions USA, Inc., Abbott, Eurofins Scientific, Beckman Coulter, Inc., 23andMe, Inc., OPKO Health, Inc., and others

Market Definition

LDTs are developed by clinical laboratories to meet specific testing needs that are not addressed by commercially available tests. They are commonly used in molecular diagnostics, genetic testing, pathology, microbiology, and other areas of clinical laboratory medicine. LDTs can encompass various tests, including genetic, oncology, infectious disease, pharmacogenomic, and others. The development of LDTs involves several stages, including test design, optimization, analytical validation, and clinical validation. Laboratories performing LDTs must comply with regulatory requirements, quality standards, and guidelines to ensure accurate and reliable test results. Regulatory oversight for LDTs varies across different countries and regions, with some jurisdictions imposing stricter regulations.

Global Laboratory-Developed Tests (LDTs) Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

DRIVERS

  • Increasing demand for personalized medicine

The increasing demand for personalized medicine has created a need for advanced diagnostic tools such as LDTs that can provide personalized and precise information about an individual's health status, enabling tailored treatment approaches and better patient outcomes. Personalized medicine tailors medical treatments and diagnostics to individual patients based on their genetic makeup, lifestyle, and other factors.

LDTs provide customized diagnostic solutions by analyzing specific genetic markers or biomarkers associated with a disease or condition. These tests enable healthcare providers to obtain detailed information about a patient's genetic profile, allowing for more precise diagnosis, prognosis, and treatment selection.

Overall, the increasing demand for personalized medicine and the need for precise diagnostic information to guide treatment decisions have been key drivers for the growth of the LDT market. As personalized medicine continues to advance, the Demand for LDTs is expected to expand further, which drives the market growth.

  • Advancements in molecular diagnostics

Advances in molecular diagnostic techniques have significantly improved the sensitivity and specificity of tests used in LDTs. These advancements enable the detection and analysis of specific genetic markers or biomarkers associated with diseases or conditions with higher accuracy and precision. The increased sensitivity and specificity of molecular diagnostics enhance the reliability and clinical utility of LDTs, making them more valuable for healthcare providers.

Molecular diagnostics advancements have led to an expanded test menu for LDTs. New molecular techniques and platforms allow for the development of tests targeting various genetic mutations, genetic variations, and biomarkers associated with various diseases. As a result, LDTs can provide more comprehensive and detailed information about an individual's health status, facilitating better diagnosis, treatment selection, and disease monitoring. Hence, advancements in molecular diagnostics have been a significant driver for market growth.

Laboratory-Developed Tests (LDTs) Market

OPPORTUNITY

  • Increasing demand for precision medicine and targeted therapy

Precision medicine aims to tailor medical treatment to the individual characteristics of each patient. It involves analyzing a patient's genetic makeup, biomarkers, and other relevant factors to determine the most effective treatment. LDTs play a crucial role in this approach by providing specialized tests that identify specific biomarkers or genetic mutations associated with certain diseases. The growing demand for personalized medicine requires more LDTs to support diagnostic and treatment decisions.

Targeted therapy is a treatment approach that focuses on specific molecular targets involved in developing and progressing diseases, such as cancer. These therapies require accurate and reliable diagnostic tests to identify patients likely to respond to targeted drugs. LDTs can be designed to detect specific genetic mutations or biomarkers that determine patients' suitability for targeted therapies. The increased adoption of targeted therapies fuels the demand for LDTs that enable precise patient stratification.

Hence, the high demand for precision medicine and targeted therapy is providing an opportunity for market growth.

RESTRAINT/CHALLENGE

  • Stringent quality control and standardization for LDTs

Quality control and standardization are essential in ensuring that LDTs meet regulatory requirements set by government agencies such as the Food and Drug Administration (FDA) in the U.SU.S. Compliance with these regulations can be time-consuming and costly, particularly for smaller laboratories and companies lacking the necessary resources and expertise. Meeting regulatory requirements can create barriers to entry for new players and inhibit market growth.

Quality control measures are necessary to validate the accuracy and reliability of LDTs. Rigorous validation studies must demonstrate that the tests produce consistent and accurate results. These studies involve testing many samples to establish sensitivity, specificity, precision, and other performance characteristics. Such studies can be resource-intensive and time-consuming, especially for complex or novel tests. The need for extensive validation can slow the introduction of new LDTs to the market, hampering its growth.

Recent Developments

  • In February 2023, Guardant Health announced that it received coverage from United Healthcare for Guardant360 CDx blood test as a companion diagnostic in advanced lung and breast cancer. This helped the company to establish its global presence
  • In May 2022, OPKO Health, Inc. acquired ModeX Therapeutics, a privately held biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious diseases. This helped the company establish its global network

Global Laboratory-developed tests (LDTs) market Segmentation

The global laboratory-developed tests (LDTs) market is segmented into eight notable segments based on test type, product type, sample type, therapeutic area, gender, age group, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Test Type

  • Clinical Chemistry and Immunology
  • Critical Care
  • Hematology
  • Molecular Diagnostics
  • Microbiology
  • Other Test

On the basis of test type, the market is segmented into clinical chemistry and immunology, critical care, hematology, molecular diagnostics, microbiology, and other test.

Product Type

  • Consumables
  • Analyzers and Instruments
  • Accessories

On the basis of product type, the market is segmented into consumables, analyzers & instruments, and accessories.

Sample Type

  • Blood
  • Urine
  • Tissue
  • Cerebrospinal fluid (CSF)
  • Others.

On the basis of sample type, the market is segmented into blood, urine, tissue, cerebrospinal fluid (CSF), and others.

Therapeutic Area

  • Infections
  • Genetic Disorders
  • Oncology/Cancer
  • Autoimmune Disease
  • Urology
  • Gynecology
  • Others

On the basis of therapeutic area, the market is segmented into infections, genetic disorders, oncology/cancer, autoimmune disease, urology, gynecology, and others.

Gender

  • Male
  • Female

On the basis of gender, the market is segmented into male, and female.

Age Group

  • Geriatrics
  • Adults
  • Pediatric

On the basis of age group, the market is segmented into geriatrics, adult, and pediatric.

End User

  • Hospital-Based Labs
  • Stand-Alone Labs
  • Diagnostic Chains
  • Academic Institutes
  • Clinical Research Organizations
  • Specialty Diagnostic Centers
  • Others

On the basis of end users, the market is segmented into hospital-based labs, stand-alone labs, diagnostic chains, academic institutes, clinical research organizations, specialty diagnostic centers, and others.

Distribution Channel

  • Direct Tender
  • Retail Slaes
  • Third Party Distribution
  • Others

On the basis of distribution channel, the market is segmented into direct tender, retail sales, third party distributors, and others.

Laboratory-Developed Tests (LDTs) Market

Global Laboratory-developed tests (LDTs) market Regional Analysis/Insights

The global laboratory-developed tests (LDTs) market is analyzed, and market size insights and trends are provided based on test type, product type, sample type, therapeutic area, gender, age group, end user, and distribution channel.

The countries covered in this market report are the U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, and Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and rest of Middle East and Africa.

North America is expected to dominate the global laboratory-developed tests (LDTs) market because of the rising awareness and government funding for laboratory developed tests. The U.S. is expected to dominate the market because of the increasing strategic initiatives by major market players.. Germany is expected to dominate the Europe region due to rising healthcare expenditure and the increased global presence of key market players. China is expected to dominate the Asia-Pacific region due to the growing expenses on the overall development of healthcare infrastructure.

The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Laboratory-Developed Tests (LDTs) Market

Competitive Landscape and Global Laboratory-developed tests (LDTs) market Share Analysis

The global Laboratory-developed tests (LDTs) market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies focus on the market.

Some of the major market players operating in the market are . Hoffmann-La Roche Ltd, bioMérieux, Inc., Sysmex Corporation, Biomerica, Inc., and Bio-Rad Laboratories, Inc. , BD, Quest Diagnostics Incorporated, Hologic, Inc., Siemens Medical Solutions USA, Inc., Abbott, Eurofins Scientific, Beckman Coulter, Inc., 23andMe, Inc., OPKO Health, Inc., and others.


SKU-

TABLE 1 NUMBER OF GENETIC TESTING LABORATORIES IN EU

TABLE 2 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 3 GLOBAL CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 GLOBAL CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 5 GLOBAL GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION))

TABLE 6 GLOBAL METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 7 GLOBAL LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 8 GLOBAL URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 9 GLOBAL CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 GLOBAL CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION))

TABLE 11 GLOBAL HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 GLOBAL HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)))

TABLE 13 GLOBAL COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 14 GLOBAL MOLECULAR DIAGNOSTIC IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 GLOBAL MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 16 GLOBAL MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 17 GLOBAL MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 18 GLOBAL MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 19 GLOBAL MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 GLOBAL MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION))

TABLE 21 GLOBAL OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 GLOBAL OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 23 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 24 GLOBAL CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 GLOBAL CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 26 GLOBAL ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 GLOBAL ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 28 GLOBAL ACCESSORIES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 30 GLOBAL BLOOD IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 GLOBAL URINE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 GLOBAL TISSUE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 GLOBAL CEREBROSPINAL FLUID (CSF) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 GLOBAL OTHERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 36 GLOBAL INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 GLOBAL INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 38 GLOBAL GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 GLOBAL GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 40 GLOBAL ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 41 GLOBAL ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 42 GLOBAL AUTOIMMUNE DISEASE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 GLOBAL UROLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 GLOBAL GYNECOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 45 GLOBAL OTHERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 47 GLOBAL MALE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 GLOBAL FEMALE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 49 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 50 GLOBAL GERIATRICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 51 GLOBAL ADULT IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 52 GLOBAL PEDIATRICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 53 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 54 GLOBAL HOSPITAL-BASED LAB IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 55 GLOBAL STAND- ALONE LABS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 56 GLOBAL DIAGNOSTIC CHAINS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 57 GLOBAL ACADEMIC INSTITUTES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 58 GLOBAL CLINICAL RESEARCH ORGANISATION IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 59 GLOBAL SPECIALTY DIAGNOSTIC IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 60 GLOBAL OTHERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 61 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 62 GLOBAL DIRECT TENDER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 63 GLOBAL RETAIL SALES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 64 GLOBAL DIRECT TENDER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 65 GLOBAL OTHERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 66 GLOBAL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 67 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 68 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 69 NORTH AMERICA CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 70 NORTH AMERICA GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 71 NORTH AMERICA METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 72 NORTH AMERICA LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 73 NORTH AMERICA URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 74 NORTH AMERICA CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 75 NORTH AMERICA HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 76 NORTH AMERICA COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 77 NORTH AMERICA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 78 NORTH AMERICA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 79 NORTH AMERICA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 80 NORTH AMERICA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 81 NORTH AMERICA MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 82 NORTH AMERICA OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 83 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 84 NORTH AMERICA CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 85 NORTH AMERICA ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 86 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 87 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 88 NORTH AMERICA INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 89 NORTH AMERICA GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 90 NORTH AMERICA ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 91 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 92 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 93 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 94 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 95 U.S. LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 96 U.S. CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 97 U.S. GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 98 U.S. METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 99 U.S. LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 100 U.S. URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 101 U.S. CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 102 U.S. HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 103 U.S. COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 104 U.S. MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 105 U.S. MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 106 U.S. MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 107 U.S. MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 108 U.S. MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 109 U.S. OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 110 U.S. LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 111 U.S. CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 112 U.S. ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 113 U.S. LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 114 U.S. LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 115 U.S. INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 116 U.S. GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 117 U.S. ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 118 U.S. LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 119 U.S. LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 120 U.S. LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 121 U.S. LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 122 CANADA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 123 CANADA CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 124 CANADA GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 125 CANADA METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 126 CANADA LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 127 CANADA URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 128 CANADA CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 129 CANADA HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 130 CANADA COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 131 CANADA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 132 CANADA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 133 CANADA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 134 CANADA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 135 CANADA MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 136 CANADA OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 137 CANADA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 138 CANADA CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 139 CANADA ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 140 CANADA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 141 CANADA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 142 CANADA INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 143 CANADA GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 144 CANADA ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 145 CANADA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 146 CANADA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 147 CANADA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 148 CANADA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 149 MEXICO LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 150 MEXICO CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 151 MEXICO GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 152 MEXICO METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 153 MEXICO LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 154 MEXICO URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 155 MEXICO CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 156 MEXICO HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 157 MEXICO COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 158 MEXICO MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 159 MEXICO MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 160 MEXICO MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 161 MEXICO MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 162 MEXICO MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 163 MEXICO OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 164 MEXICO LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 165 MEXICO CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 166 MEXICO ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 167 MEXICO LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 168 MEXICO LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 169 MEXICO INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 170 MEXICO GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 171 MEXICO ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 172 MEXICO LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 173 MEXICO LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 174 MEXICO LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 175 MEXICO LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 176 EUROPE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 177 EUROPE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 178 EUROPE CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 179 EUROPE GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 180 EUROPE METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 181 EUROPE LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 182 EUROPE URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 183 EUROPE CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 184 EUROPE HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 185 EUROPE COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 186 EUROPE MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 187 EUROPE MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 188 EUROPE MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 189 EUROPE MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 190 EUROPE MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 191 EUROPE OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 192 EUROPE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 193 EUROPE CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 194 EUROPE ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 195 EUROPE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 196 EUROPE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 197 EUROPE INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 198 EUROPE GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 199 EUROPE ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 200 EUROPE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 201 EUROPE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 202 EUROPE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 203 EUROPE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 204 GERMANY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 205 GERMANY CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 206 GERMANY GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 207 GERMANY METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 208 GERMANY LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 209 GERMANY URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 210 GERMANY CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 211 GERMANY HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 212 GERMANY COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 213 GERMANY MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 214 GERMANY MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 215 GERMANY MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 216 GERMANY MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 217 GERMANY MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 218 GERMANY OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 219 GERMANY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 220 GERMANY CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 221 GERMANY ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 222 GERMANY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 223 GERMANY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 224 GERMANY INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 225 GERMANY GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 226 GERMANY ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 227 GERMANY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 228 GERMANY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 229 GERMANY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 230 GERMANY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 231 U.K. LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 232 U.K. CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 233 U.K. GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 234 U.K. METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 235 U.K. LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 236 U.K. URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 237 U.K. CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 238 U.K. HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 239 U.K. COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 240 U.K. MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 241 U.K. MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 242 U.K. MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 243 U.K. MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 244 U.K. MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 245 U.K. OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 246 U.K. LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 247 U.K. CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 248 U.K. ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 249 U.K. LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 250 U.K. LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 251 U.K. INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 252 U.K. GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 253 U.K. ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 254 U.K. LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 255 U.K. LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 256 U.K. LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 257 U.K. LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 258 FRANCE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 259 FRANCE CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 260 FRANCE GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 261 FRANCE METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 262 FRANCE LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 263 FRANCE URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 264 FRANCE CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 265 FRANCE HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 266 FRANCE COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 267 FRANCE MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 268 FRANCE MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 269 FRANCE MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 270 FRANCE MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 271 FRANCE MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 272 FRANCE OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 273 FRANCE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 274 FRANCE CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 275 FRANCE ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 276 FRANCE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 277 FRANCE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 278 FRANCE INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 279 FRANCE GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 280 FRANCE ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 281 FRANCE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 282 FRANCE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 283 FRANCE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 284 FRANCE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 285 ITALY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 286 ITALY CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 287 ITALY GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 288 ITALY METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 289 ITALY LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 290 ITALY URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 291 ITALY CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 292 ITALY HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 293 ITALY COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 294 ITALY MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 295 ITALY MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 296 ITALY MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 297 ITALY MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 298 ITALY MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 299 ITALY OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 300 ITALY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 301 ITALY CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 302 ITALY ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 303 ITALY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 304 ITALY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 305 ITALY INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 306 ITALY GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 307 ITALY ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 308 ITALY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 309 ITALY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 310 ITALY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 311 ITALY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 312 RUSSIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 313 RUSSIA CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 314 RUSSIA GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 315 RUSSIA METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 316 RUSSIA LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 317 RUSSIA URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 318 RUSSIA CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 319 RUSSIA HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 320 RUSSIA COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 321 RUSSIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 322 RUSSIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 323 RUSSIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 324 RUSSIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 325 RUSSIA MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 326 RUSSIA OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 327 RUSSIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 328 RUSSIA CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 329 RUSSIA ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 330 RUSSIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 331 RUSSIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 332 RUSSIA INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 333 RUSSIA GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 334 RUSSIA ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 335 RUSSIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 336 RUSSIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 337 RUSSIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 338 RUSSIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 339 SPAIN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 340 SPAIN CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 341 SPAIN GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 342 SPAIN METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 343 SPAIN LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 344 SPAIN URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 345 SPAIN CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 346 SPAIN HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 347 SPAIN COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 348 SPAIN MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 349 SPAIN MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 350 SPAIN MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 351 SPAIN MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 352 SPAIN MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 353 SPAIN OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 354 SPAIN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 355 SPAIN CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 356 SPAIN ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 357 SPAIN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 358 SPAIN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 359 SPAIN INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 360 SPAIN GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 361 SPAIN ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 362 SPAIN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 363 SPAIN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 364 SPAIN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 365 SPAIN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 366 NETHERLANDS LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 367 NETHERLANDS CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 368 NETHERLANDS GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 369 NETHERLANDS METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 370 NETHERLANDS LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 371 NETHERLANDS URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 372 NETHERLANDS CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 373 NETHERLANDS HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 374 NETHERLANDS COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 375 NETHERLANDS MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 376 NETHERLANDS MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 377 NETHERLANDS MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 378 NETHERLANDS MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 379 NETHERLANDS MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 380 NETHERLANDS OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 381 NETHERLANDS LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 382 NETHERLANDS CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 383 NETHERLANDS ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 384 NETHERLANDS LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 385 NETHERLANDS LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 386 NETHERLANDS INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 387 NETHERLANDS GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 388 NETHERLANDS ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 389 NETHERLANDS LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 390 NETHERLANDS LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 391 NETHERLANDS LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 392 NETHERLANDS LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 393 SWITZERLAND LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 394 SWITZERLAND CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 395 SWITZERLAND GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 396 SWITZERLAND METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 397 SWITZERLAND LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 398 SWITZERLAND URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 399 SWITZERLAND CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 400 SWITZERLAND HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 401 SWITZERLAND COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 402 SWITZERLAND MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 403 SWITZERLAND MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 404 SWITZERLAND MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 405 SWITZERLAND MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 406 SWITZERLAND MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 407 SWITZERLAND OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 408 SWITZERLAND LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 409 SWITZERLAND CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 410 SWITZERLAND ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 411 SWITZERLAND LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 412 SWITZERLAND LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 413 SWITZERLAND INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 414 SWITZERLAND GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 415 SWITZERLAND ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 416 SWITZERLAND LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 417 SWITZERLAND LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 418 SWITZERLAND LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 419 SWITZERLAND LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 420 BELGIUM LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 421 BELGIUM CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 422 BELGIUM GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 423 BELGIUM METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 424 BELGIUM LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 425 BELGIUM URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 426 BELGIUM CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 427 BELGIUM HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 428 BELGIUM COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 429 BELGIUM MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 430 BELGIUM MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 431 BELGIUM MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 432 BELGIUM MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 433 BELGIUM MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 434 BELGIUM OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 435 BELGIUM LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 436 BELGIUM CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 437 BELGIUM ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 438 BELGIUM LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 439 BELGIUM LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 440 BELGIUM INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 441 BELGIUM GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 442 BELGIUM ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 443 BELGIUM LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 444 BELGIUM LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 445 BELGIUM LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 446 BELGIUM LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 447 TURKEY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 448 TURKEY CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 449 TURKEY GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 450 TURKEY METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 451 TURKEY LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 452 TURKEY URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 453 TURKEY CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 454 TURKEY HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 455 TURKEY COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 456 TURKEY MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 457 TURKEY MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 458 TURKEY MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 459 TURKEY MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 460 TURKEY MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 461 TURKEY OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 462 TURKEY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 463 TURKEY CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 464 TURKEY ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 465 TURKEY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 466 TURKEY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 467 TURKEY INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 468 TURKEY GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 469 TURKEY ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 470 TURKEY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 471 TURKEY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 472 TURKEY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 473 TURKEY LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 474 REST OF EUROPE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 475 ASIA-PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 476 ASIA-PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 477 ASIA-PACIFIC CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 478 ASIA-PACIFIC GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 479 ASIA-PACIFIC METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 480 ASIA-PACIFIC LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 481 ASIA-PACIFIC URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 482 ASIA-PACIFIC CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 483 ASIA-PACIFIC HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 484 ASIA-PACIFIC COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 485 ASIA-PACIFIC MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 486 ASIA-PACIFIC MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 487 ASIA-PACIFIC MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 488 ASIA-PACIFIC MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 489 ASIA-PACIFIC MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 490 ASIA-PACIFIC OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 491 ASIA-PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 492 ASIA-PACIFIC CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 493 ASIA-PACIFIC ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 494 ASIA-PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 495 ASIA-PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 496 ASIA-PACIFIC INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 497 ASIA-PACIFIC GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 498 ASIA-PACIFIC ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 499 ASIA-PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 500 ASIA-PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 501 ASIA-PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 502 ASIA-PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 503 CHINA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 504 CHINA CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 505 CHINA GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 506 CHINA METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 507 CHINA LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 508 CHINA URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 509 CHINA CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 510 CHINA HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 511 CHINA COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 512 CHINA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 513 CHINA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 514 CHINA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 515 CHINA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 516 CHINA MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 517 CHINA OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 518 CHINA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 519 CHINA CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 520 CHINA ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 521 CHINA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 522 CHINA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 523 CHINA INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 524 CHINA GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 525 CHINA ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 526 CHINA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 527 CHINA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 528 CHINA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 529 CHINA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 530 JAPAN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 531 JAPAN CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 532 JAPAN GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 533 JAPAN METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 534 JAPAN LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 535 JAPAN URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 536 JAPAN CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 537 JAPAN HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 538 JAPAN COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 539 JAPAN MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 540 JAPAN MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 541 JAPAN MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 542 JAPAN MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 543 JAPAN MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 544 JAPAN OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 545 JAPAN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 546 JAPAN CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 547 JAPAN ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 548 JAPAN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 549 JAPAN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 550 JAPAN INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 551 JAPAN GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 552 JAPAN ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 553 JAPAN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 554 JAPAN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 555 JAPAN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 556 JAPAN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 557 INDIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 558 INDIA CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 559 INDIA GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 560 INDIA METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 561 INDIA LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 562 INDIA URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 563 INDIA CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 564 INDIA HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 565 INDIA COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 566 INDIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 567 INDIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 568 INDIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 569 INDIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 570 INDIA MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 571 INDIA OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 572 INDIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 573 INDIA CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 574 INDIA ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 575 INDIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 576 INDIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 577 INDIA INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 578 INDIA GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 579 INDIA ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 580 INDIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 581 INDIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 582 INDIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 583 INDIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 584 AUSTRALIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 585 AUSTRALIA CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 586 AUSTRALIA GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 587 AUSTRALIA METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 588 AUSTRALIA LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 589 AUSTRALIA URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 590 AUSTRALIA CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 591 AUSTRALIA HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 592 AUSTRALIA COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 593 AUSTRALIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 594 AUSTRALIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 595 AUSTRALIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 596 AUSTRALIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 597 AUSTRALIA MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 598 AUSTRALIA OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 599 AUSTRALIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 600 AUSTRALIA CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 601 AUSTRALIA ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 602 AUSTRALIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 603 AUSTRALIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 604 AUSTRALIA INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 605 AUSTRALIA GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 606 AUSTRALIA ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 607 AUSTRALIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 608 AUSTRALIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 609 AUSTRALIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 610 AUSTRALIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 611 SOUTH KOREA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 612 SOUTH KOREA CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 613 SOUTH KOREA GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 614 SOUTH KOREA METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 615 SOUTH KOREA LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 616 SOUTH KOREA URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 617 SOUTH KOREA CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 618 SOUTH KOREA HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 619 SOUTH KOREA COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 620 SOUTH KOREA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 621 SOUTH KOREA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 622 SOUTH KOREA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 623 SOUTH KOREA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 624 SOUTH KOREA MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 625 SOUTH KOREA OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 626 SOUTH KOREA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 627 SOUTH KOREA CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 628 SOUTH KOREA ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 629 SOUTH KOREA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 630 SOUTH KOREA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 631 SOUTH KOREA INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 632 SOUTH KOREA GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 633 SOUTH KOREA ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 634 SOUTH KOREA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 635 SOUTH KOREA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 636 SOUTH KOREA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 637 SOUTH KOREA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 638 INDONESIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 639 INDONESIA CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 640 INDONESIA GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 641 INDONESIA METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 642 INDONESIA LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 643 INDONESIA URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 644 INDONESIA CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 645 INDONESIA HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 646 INDONESIA COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 647 INDONESIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 648 INDONESIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 649 INDONESIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 650 INDONESIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 651 INDONESIA MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 652 INDONESIA OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 653 INDONESIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 654 INDONESIA CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 655 INDONESIA ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 656 INDONESIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 657 INDONESIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 658 INDONESIA INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 659 INDONESIA GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 660 INDONESIA ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 661 INDONESIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 662 INDONESIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 663 INDONESIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 664 INDONESIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 665 PHILIPPINES LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 666 PHILIPPINES CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 667 PHILIPPINES GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 668 PHILIPPINES METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 669 PHILIPPINES LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 670 PHILIPPINES URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 671 PHILIPPINES CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 672 PHILIPPINES HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 673 PHILIPPINES COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 674 PHILIPPINES MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 675 PHILIPPINES MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 676 PHILIPPINES MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 677 PHILIPPINES MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 678 PHILIPPINES MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 679 PHILIPPINES OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 680 PHILIPPINES LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 681 PHILIPPINES CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 682 PHILIPPINES ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 683 PHILIPPINES LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 684 PHILIPPINES LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 685 PHILIPPINES INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 686 PHILIPPINES GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 687 PHILIPPINES ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 688 PHILIPPINES LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 689 PHILIPPINES LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 690 PHILIPPINES LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 691 PHILIPPINES LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 692 THAILAND LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 693 THAILAND CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 694 THAILAND GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 695 THAILAND METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 696 THAILAND LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 697 THAILAND URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 698 THAILAND CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 699 THAILAND HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 700 THAILAND COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 701 THAILAND MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 702 THAILAND MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 703 THAILAND MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 704 THAILAND MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 705 THAILAND MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 706 THAILAND OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 707 THAILAND LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 708 THAILAND CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 709 THAILAND ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 710 THAILAND LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 711 THAILAND LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 712 THAILAND INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 713 THAILAND GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 714 THAILAND ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 715 THAILAND LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 716 THAILAND LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 717 THAILAND LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 718 THAILAND LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 719 MALAYSIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 720 MALAYSIA CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 721 MALAYSIA GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 722 MALAYSIA METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 723 MALAYSIA LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 724 MALAYSIA URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 725 MALAYSIA CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 726 MALAYSIA HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 727 MALAYSIA COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 728 MALAYSIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 729 MALAYSIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 730 MALAYSIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 731 MALAYSIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 732 MALAYSIA MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 733 MALAYSIA OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 734 MALAYSIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 735 MALAYSIA CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 736 MALAYSIA ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 737 MALAYSIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 738 MALAYSIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 739 MALAYSIA INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 740 MALAYSIA GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 741 MALAYSIA ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 742 MALAYSIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 743 MALAYSIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 744 MALAYSIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 745 MALAYSIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 746 SINGAPORE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 747 SINGAPORE CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 748 SINGAPORE GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 749 SINGAPORE METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 750 SINGAPORE LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 751 SINGAPORE URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 752 SINGAPORE CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 753 SINGAPORE HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 754 SINGAPORE COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 755 SINGAPORE MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 756 SINGAPORE MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 757 SINGAPORE MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 758 SINGAPORE MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 759 SINGAPORE MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 760 SINGAPORE OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 761 SINGAPORE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 762 SINGAPORE CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 763 SINGAPORE ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 764 SINGAPORE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 765 SINGAPORE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 766 SINGAPORE INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 767 SINGAPORE GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 768 SINGAPORE ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 769 SINGAPORE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 770 SINGAPORE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 771 SINGAPORE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 772 SINGAPORE LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 773 REST OF ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 774 SOUTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 775 SOUTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 776 SOUTH AMERICA CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 777 SOUTH AMERICA GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 778 SOUTH AMERICA METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 779 SOUTH AMERICA LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 780 SOUTH AMERICA URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 781 SOUTH AMERICA CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 782 SOUTH AMERICA HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 783 SOUTH AMERICA COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 784 SOUTH AMERICA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 785 SOUTH AMERICA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 786 SOUTH AMERICA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 787 SOUTH AMERICA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 788 SOUTH AMERICA MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 789 SOUTH AMERICA OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 790 SOUTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 791 SOUTH AMERICA CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 792 SOUTH AMERICA ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 793 SOUTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 794 SOUTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 795 SOUTH AMERICA INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 796 SOUTH AMERICA GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 797 SOUTH AMERICA ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 798 SOUTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 799 SOUTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 800 SOUTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 801 SOUTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 802 BRAZIL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 803 BRAZIL CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 804 BRAZIL GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 805 BRAZIL METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 806 BRAZIL LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 807 BRAZIL URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 808 BRAZIL CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 809 BRAZIL HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 810 BRAZIL COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 811 BRAZIL MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 812 BRAZIL MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 813 BRAZIL MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 814 BRAZIL MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 815 BRAZIL MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 816 BRAZIL OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 817 BRAZIL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 818 BRAZIL CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 819 BRAZIL ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 820 BRAZIL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 821 BRAZIL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 822 BRAZIL INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 823 BRAZIL GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 824 BRAZIL ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 825 BRAZIL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 826 BRAZIL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 827 BRAZIL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 828 BRAZIL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 829 ARGENTINA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 830 ARGENTINA CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 831 ARGENTINA GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 832 ARGENTINA METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 833 ARGENTINA LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 834 ARGENTINA URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 835 ARGENTINA CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 836 ARGENTINA HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 837 ARGENTINA COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 838 ARGENTINA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 839 ARGENTINA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 840 ARGENTINA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 841 ARGENTINA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 842 ARGENTINA MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 843 ARGENTINA OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 844 ARGENTINA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 845 ARGENTINA CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 846 ARGENTINA ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 847 ARGENTINA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 848 ARGENTINA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 849 ARGENTINA INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 850 ARGENTINA GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 851 ARGENTINA ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 852 ARGENTINA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 853 ARGENTINA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 854 ARGENTINA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 855 ARGENTINA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 856 REST OF SOUTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 857 MIDDLE EAST AND AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 858 MIDDLE EAST AND AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 859 MIDDLE EAST AND AFRICA CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 860 MIDDLE EAST AND AFRICA GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 861 MIDDLE EAST AND AFRICA METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 862 MIDDLE EAST AND AFRICA LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 863 MIDDLE EAST AND AFRICA URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 864 MIDDLE EAST AND AFRICA CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 865 MIDDLE EAST AND AFRICA HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 866 MIDDLE EAST AND AFRICA COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 867 MIDDLE EAST AND AFRICA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 868 MIDDLE EAST AND AFRICA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 869 MIDDLE EAST AND AFRICA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 870 MIDDLE EAST AND AFRICA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 871 MIDDLE EAST AND AFRICA MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 872 MIDDLE EAST AND AFRICA OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 873 MIDDLE EAST AND AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 874 MIDDLE EAST AND AFRICA CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 875 MIDDLE EAST AND AFRICA ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 876 MIDDLE EAST AND AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 877 MIDDLE EAST AND AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 878 MIDDLE EAST AND AFRICA INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 879 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 880 MIDDLE EAST AND AFRICA ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 881 MIDDLE EAST AND AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 882 MIDDLE EAST AND AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 883 MIDDLE EAST AND AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 884 MIDDLE EAST AND AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 885 SAUDI ARABIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 886 SAUDI ARABIA CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 887 SAUDI ARABIA GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 888 SAUDI ARABIA METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 889 SAUDI ARABIA LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 890 SAUDI ARABIA URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 891 SAUDI ARABIA CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 892 SAUDI ARABIA HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 893 SAUDI ARABIA COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 894 SAUDI ARABIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 895 SAUDI ARABIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 896 SAUDI ARABIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 897 SAUDI ARABIA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 898 SAUDI ARABIA MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 899 SAUDI ARABIA OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 900 SAUDI ARABIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 901 SAUDI ARABIA CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 902 SAUDI ARABIA ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 903 SAUDI ARABIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 904 SAUDI ARABIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 905 SAUDI ARABIA INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 906 SAUDI ARABIA GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 907 SAUDI ARABIA ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 908 SAUDI ARABIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 909 SAUDI ARABIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 910 SAUDI ARABIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 911 SAUDI ARABIA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 912 SOUTH AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 913 SOUTH AFRICA CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 914 SOUTH AFRICA GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 915 SOUTH AFRICA METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 916 SOUTH AFRICA LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 917 SOUTH AFRICA URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 918 SOUTH AFRICA CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 919 SOUTH AFRICA HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 920 SOUTH AFRICA COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 921 SOUTH AFRICA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 922 SOUTH AFRICA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 923 SOUTH AFRICA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 924 SOUTH AFRICA MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 925 SOUTH AFRICA MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 926 SOUTH AFRICA OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 927 SOUTH AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 928 SOUTH AFRICA CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 929 SOUTH AFRICA ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 930 SOUTH AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 931 SOUTH AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 932 SOUTH AFRICA INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 933 SOUTH AFRICA GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 934 SOUTH AFRICA ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 935 SOUTH AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 936 SOUTH AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 937 SOUTH AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 938 SOUTH AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 939 U.A.E LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 940 U.A.E CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 941 U.A.E GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 942 U.A.E METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 943 U.A.E LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 944 U.A.E URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 945 U.A.E CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 946 U.A.E HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 947 U.A.E COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 948 U.A.E MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 949 U.A.E MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 950 U.A.E MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 951 U.A.E MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 952 U.A.E MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 953 U.A.E OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 954 U.A.E LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 955 U.A.E CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 956 U.A.E ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 957 U.A.E LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 958 U.A.E LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 959 U.A.E INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 960 U.A.E GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 961 U.A.E ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 962 U.A.E LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 963 U.A.E LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 964 U.A.E LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 965 U.A.E LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 966 EGYPT LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 967 EGYPT CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 968 EGYPT GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 969 EGYPT METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 970 EGYPT LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 971 EGYPT URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 972 EGYPT CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 973 EGYPT HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 974 EGYPT COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 975 EGYPT MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 976 EGYPT MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 977 EGYPT MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 978 EGYPT MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 979 EGYPT MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 980 EGYPT OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 981 EGYPT LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 982 EGYPT CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 983 EGYPT ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 984 EGYPT LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 985 EGYPT LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 986 EGYPT INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 987 EGYPT GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 988 EGYPT ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 989 EGYPT LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 990 EGYPT LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 991 EGYPT LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 992 EGYPT LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 993 ISRAEL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 994 ISRAEL CLINICAL CHEMISTRY AND IMMUNOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 995 ISRAEL GLUCOSE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 996 ISRAEL METABOLIC PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 997 ISRAEL LIVER PANEL IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 998 ISRAEL URINALYSIS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 999 ISRAEL CRITICAL CARE IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 1000 ISRAEL HAEMATOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 1001 ISRAEL COMPLETE BLOOD COUNT (CBC) IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 1002 ISRAEL MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 1003 ISRAEL MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 1004 ISRAEL MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 1005 ISRAEL MOLECULAR DIAGNOSTICS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 1006 ISRAEL MICROBIOLOGY IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 1007 ISRAEL OTHER TEST IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 1008 ISRAEL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 1009 ISRAEL CONSUMABLES IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 1010 ISRAEL ANALYZERS AND INSTRUMENTS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 1011 ISRAEL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 1012 ISRAEL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 1013 ISRAEL INFECTIONS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 1014 ISRAEL GENETIC DISORDERS IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 1015 ISRAEL ONCOLOGY/CANCER IN LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 1016 ISRAEL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 1017 ISRAEL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 1018 ISRAEL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USERS, 2021-2030 (USD MILLION)

TABLE 1019 ISRAEL LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 1020 REST OF MIDDLE EAST AND AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The growth rate of the Laboratory-Developed Tests (LDTs) Market is 10.7% by 2030.
Increasing demand for personalized medicine is the growth driver of the laboratory-Developed Tests (LDTs) Market.
The major companies in the Laboratory-Developed Tests (LDTs) Market are Abbott (US), Danaher. (US), bioMérieux (France), F. Hoffmann-La Roche Ltd (Switzerland), Quidel Corporation (US)., Mesa Biotech, Inc (US), GenePOC Inc., Spartan Bioscience Inc. (Canada), Biocartis (Belgium), Siemens Healthcare Private Limited (Germany), BD (US), Bio-Rad Laboratories, Inc. (US), Cepheid (US), Abaxis (US), OraSure Technologies, Inc. (US), Sysmex Corporation (Japan), Thermo Fisher Scientific Inc. (US), and VIRCELL S.L.(Spain).
Academic Institutes, Clinical Research Organizations, Hospitals Laboratory, Specialty Diagnostic Centers, and Other Type of Facilities are the market applications of the Laboratory-Developed Tests (LDTs) Market.
Test type, product type, sample type, therapeutic area, gender, age group, end user, and distribution channel are the factors on which the Laboratory-Developed Tests (LDTs) Market research is based.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials